AbVacc Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Private

  • Employees
  • 43

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1M

  • Investors
  • 10

AbVacc General Information

Description

Developer of a research-based healthcare platform intended to help control infectious diseases. The company's platform specializes in toxin-based vaccines that protect against all ebolaviruses, a common cause of both hospital-acquired and community-acquired infections and bacterial sepsis, and also discover novel vaccines and therapeutics, enabling healthcare providers to treat emerging infectious diseases.

Contact Information

Website
www.abvacc.com
Formerly Known As
Integrated BioTherapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 4 Research Court
  • Suite 310
  • Rockville, MD 20850
  • United States
+1 (877) 000-0000

AbVacc Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AbVacc Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
20. Later Stage VC 10-May-2023 $1M 00.000 Completed Generating Revenue
19. Grant 12-May-2021 000 00.000 Completed Generating Revenue
18. Grant 06-Jul-2020 00000 00.000 Completed Generating Revenue
17. Debt - PPP 28-Apr-2020 00000 00.000 Completed Generating Revenue
16. Grant 12-Mar-2020 00000 00.000 Completed Generating Revenue
15. Later Stage VC 06-Jan-2020 00.00 00.000 Completed Generating Revenue
14. Grant 01-Jan-2020 00.000 0000 Completed Generating Revenue
13. Grant 12-Jul-2019 00000 0000 Completed Generating Revenue
12. Grant 14-Mar-2019 $731K $75K Completed Generating Revenue
11. Grant 01-Aug-2017 $6.77M $75K Completed Generating Revenue
To view AbVacc’s complete valuation and funding history, request access »

AbVacc Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a research-based healthcare platform intended to help control infectious diseases. The company's platform s
Drug Discovery
Rockville, MD
43 As of 2023
00.000
0000000000 0 00.000

000 00

e cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
0000 000000000
Cambridge, MA
000 As of 0000
000.00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AbVacc Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
VBI Vaccines Corporation Cambridge, MA 000 000.00 00000000 000.00
You’re viewing 1 of 1 competitors. Get the full list »

AbVacc Patents

AbVacc Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220257744-A1 Immunogenic composition comprising a fusion peptide derived from superantigen toxoids Active 27-Jul-2017 0000000000
US-11260120-B2 Immunogenic composition comprising a fusion peptide derived from superantigen toxoids Active 27-Jul-2017 0000000000 00
US-20200206335-A1 Immunogenic composition comprising a fusion peptide derived from superantigen toxoids Active 27-Jul-2017 0000000000
US-11826412-B2 Immunogenic composition comprising a fusion peptide derived from superantigen toxoids Active 27-Jul-2017 0000000000 00
US-11421021-B2 Immunogenic compositions comprising staphylococcus aureus leukocidin luka and lukb derived polypeptides Active 13-Jun-2017 A61K39/085 0
To view AbVacc’s complete patent history, request access »

AbVacc Executive Team (4)

Name Title Board Seat
Javad Aman Ph.D Chief Scientific Officer, and President
Mahtab Hekmat Director of Finance & Administration
You’re viewing 2 of 4 executive team members. Get the full list »

AbVacc Board Members (4)

Name Representing Role Since
Bruce Forrest MD Self Board Member 000 0000
Clement Lewin Ph.D Self Board Member 000 0000
Michael Hodges MD Self Board Member 000 0000
Tarun Dengi Self Board Member 000 0000
To view AbVacc’s complete board members history, request access »

AbVacc Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AbVacc Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institutes of Health Government 000 0000 000000 0
Novo Holdings Asset Manager Minority 000 0000 000000 0
CARB-X University 000 0000 000000 0
National Institute Of Allergy and Infectious Diseases Government 000 0000 000000 0
National Institute for Allergy and Infectious Disease Government 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

AbVacc FAQs

  • When was AbVacc founded?

    AbVacc was founded in 2005.

  • Who is the founder of AbVacc?

    Javad Aman Ph.D and Kelly Warfield Ph.D are the founders of AbVacc.

  • Where is AbVacc headquartered?

    AbVacc is headquartered in Rockville, MD.

  • What is the size of AbVacc?

    AbVacc has 43 total employees.

  • What industry is AbVacc in?

    AbVacc’s primary industry is Drug Discovery.

  • Is AbVacc a private or public company?

    AbVacc is a Private company.

  • What is AbVacc’s current revenue?

    The current revenue for AbVacc is 00000.

  • How much funding has AbVacc raised over time?

    AbVacc has raised $4.97M.

  • Who are AbVacc’s investors?

    National Institutes of Health, Novo Holdings, CARB-X, National Institute Of Allergy and Infectious Diseases, and National Institute for Allergy and Infectious Disease are 5 of 10 investors who have invested in AbVacc.

  • Who are AbVacc’s competitors?

    VBI Vaccines is a competitor of AbVacc.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »